BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mukherjee TI, Pillai V, Ali SH, Altice FL, Kamarulzaman A, Wickersham JA. Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. Int J Drug Policy 2017;47:144-52. [PMID: 28652072 DOI: 10.1016/j.drugpo.2017.05.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Buggisch P, Heiken H, Mauss S, Weber B, Jung MC, Görne H, Heyne R, Hinrichsen H, Hidde D, König B, Pires Dos Santos AG, Niederau C, Berg T. Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study. PLoS One 2021;16:e0250833. [PMID: 33970940 DOI: 10.1371/journal.pone.0250833] [Reference Citation Analysis]
2 Zhang JY, Li ZB, Zhang L, Wang J, Huang LP, Zhan GL, Li Z, Du J, Zhao M. DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China. BMC Infect Dis 2019;19:774. [PMID: 31488064 DOI: 10.1186/s12879-019-4421-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Kilonzo SB, Gunda DW, Majinge DC, Jaka H, Manyiri PM, Kalokola F, Mtui G, Shao ER, Bakshi FA, Stephano A. Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study. BMC Infect Dis 2021;21:699. [PMID: 34289801 DOI: 10.1186/s12879-021-06393-0] [Reference Citation Analysis]
4 Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, Treloar C. Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. International Journal of Drug Policy 2017;47:26-33. [DOI: 10.1016/j.drugpo.2017.08.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
5 Valerio H, McAuley A, Innes H, Palmateer N, Goldberg DJ, Munro A, Taylor A, Hutchinson SJ. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. Int J Drug Policy 2018;52:115-22. [PMID: 29414462 DOI: 10.1016/j.drugpo.2017.12.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
6 Patel EU, Solomon SS, Mcfall AM, Srikrishnan AK, Pradeep A, Nandagopal P, Laeyendecker O, Tobian AAR, Thomas DL, Sulkowski MS, Kumar MS, Mehta SH. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. Int J Drug Policy 2018;57:51-60. [PMID: 29679811 DOI: 10.1016/j.drugpo.2018.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Ramlan AR, Mohamed Nazar NI, Tumian A, Ab Rahman NS, Mohamad D, Abdul Talib MS, Zakaria KFM, Izuddin MA, Zainal Abidin NA, T Syed Manso SS, Wan Hassan WNK. Time to Treatment Initiation and Retrospective Analysis of Antiretroviral Therapy Outcomes among HIV-positive Methadone Maintenance Therapy Clients in Primary Health-care Centers, Kuantan, Pahang. J Pharm Bioallied Sci 2020;12:S810-5. [PMID: 33828381 DOI: 10.4103/jpbs.JPBS_3_20] [Reference Citation Analysis]